Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Recombinant human thyroid stimulating hormone-Suzhou Zelgen Biopharmaceuticals (Primary)
Indications Carcinoma; Thyroid cancer
Focus Adverse reactions
Sponsors Suzhou Zelgen Biopharmaceuticals

28 Nov 2022 Status changed from recruiting to completed.
14 Dec 2020 Planned End Date changed from 30 Dec 2020 to 30 Dec 2022.
14 Dec 2020 Planned primary completion date changed from 30 Oct 2020 to 30 Dec 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com